{
    "clinical_study": {
        "@rank": "70438", 
        "arm_group": [
            {
                "arm_group_label": "Fidaxomicin", 
                "arm_group_type": "Active Comparator", 
                "description": "Fidaxomicin 200mg by mouth every 12 hours for 10 days"
            }, 
            {
                "arm_group_label": "Vancomycin", 
                "arm_group_type": "Active Comparator", 
                "description": "Vancomycin 125mg by mouth every 6 hours for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare number of vegetative cells and spores in stool over\n      time for fidaxomicin or vancomycin in patients diagnosed with their first episode of C.\n      difficile infection."
        }, 
        "brief_title": "Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Clostridium Difficile Infection", 
        "condition_browse": {
            "mesh_term": "Clostridium Infections"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to:\n\n        -  Compare quantitatively the number of vegetative cells in stool over time for\n           fidaxomicin or vancomycin in patients diagnosed with their first episode of C.\n           difficile infection\n\n        -  Compare quantitatively the number of spores in the stool over time for patients\n           presenting with their first episode of C. difficile infection having been treated with\n           either fidaxomicin or vancomycin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age and above\n\n          -  First diagnosis of C. difficile infection\n\n          -  Treatment for C. difficile infection less than 24 hours\n\n          -  Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at\n             least 1 year,  surgically sterile (i.e., documented tubal ligation or hysterectomy)\n             for at least 90 days, abstinent, or agree to use 1 of the following forms of\n             contraception from the time of signing the Informed Consent form (ICF) until 30 days\n             after leaving the study site: a nonhormonal intrauterine device (IUD) with\n             spermicide, female condom with spermicide, contraceptive sponge with spermicide,\n             diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who\n             agrees to use a male condom with spermicide, or a sterile sexual partner.\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to fidaxomicin or vancomycin\n\n          -  Pregnant or breast-feeding\n\n          -  Active treatment with other therapies with activity against C. difficile\n\n          -  Receiving any peristaltic agents\n\n          -  Medical history including ulcerative colitis or Chron's disease\n\n          -  Ordered to be nothing by mouth or cannot swallow the study medication\n\n          -  Participation in another clinical research study utilizing pharmacological treatment\n             within 1 month or five half-lives of the medication whichever is longer\n\n          -  Any other reason felt by the investigator to potentially affect the outcomes of the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818141", 
            "org_study_id": "NICO003785HE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vancomycin", 
                "description": "Vancomycin 125mg by mouth every 6 hours for 10 days", 
                "intervention_name": "Vancomycin", 
                "intervention_type": "Drug", 
                "other_name": "Vancomycin 125mg by mouth every 6 hours for 10 days"
            }, 
            {
                "arm_group_label": "Fidaxomicin", 
                "description": "Fidaxomicin 200mg by mouth every 12 hours for 10 days", 
                "intervention_name": "Fidaxomicin", 
                "intervention_type": "Drug", 
                "other_name": "Fidaxomicin 200mg by mouth every 12 hours for 10 days"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 21, 2013", 
        "location": {
            "contact": {
                "email": "dnicola@harthosp.org", 
                "last_name": "David P Nicolau, PharmD", 
                "phone": "860-545-3941"
            }, 
            "facility": {
                "address": {
                    "city": "Hartford", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06102"
                }, 
                "name": "Hartford Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "David P Nicolau, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Seth T Housman, PharmD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The quantity of C.difficile (vegetative cells and spores) will be determined at day 0, 3-5, 10-13, and 25-30. Those counts at day 3-5, 10-13, and 25-30 will be compared to day 0 to assess change from baseline.", 
            "measure": "The change in quantity of Clostridium difficile (both vegetative cells and spores) found within the stool of patients", 
            "safety_issue": "No", 
            "time_frame": "day 0, 3-5, 10-13, 25-30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818141"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hartford Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Optimer Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hartford Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}